Diamant Asset Management Inc. Has $3.60 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Diamant Asset Management Inc. grew its stake in Johnson & Johnson (NYSE:JNJFree Report) by 1.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 23,091 shares of the company’s stock after purchasing an additional 226 shares during the quarter. Johnson & Johnson comprises 3.0% of Diamant Asset Management Inc.’s holdings, making the stock its 9th biggest position. Diamant Asset Management Inc.’s holdings in Johnson & Johnson were worth $3,596,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in JNJ. Independent Advisor Alliance lifted its holdings in shares of Johnson & Johnson by 0.9% during the second quarter. Independent Advisor Alliance now owns 153,337 shares of the company’s stock valued at $25,380,000 after purchasing an additional 1,327 shares in the last quarter. King Luther Capital Management Corp lifted its holdings in shares of Johnson & Johnson by 0.3% during the second quarter. King Luther Capital Management Corp now owns 643,435 shares of the company’s stock valued at $106,501,000 after purchasing an additional 2,027 shares in the last quarter. DORCHESTER WEALTH MANAGEMENT Co lifted its holdings in shares of Johnson & Johnson by 0.6% during the third quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock valued at $11,758,000 after purchasing an additional 414 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Johnson & Johnson by 5.1% during the second quarter. Dimensional Fund Advisors LP now owns 8,843,038 shares of the company’s stock valued at $1,463,594,000 after purchasing an additional 430,445 shares in the last quarter. Finally, Cibc World Market Inc. lifted its holdings in shares of Johnson & Johnson by 4.4% during the second quarter. Cibc World Market Inc. now owns 702,435 shares of the company’s stock valued at $116,267,000 after purchasing an additional 29,891 shares in the last quarter. 68.40% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on JNJ shares. Raymond James upped their price target on Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, January 3rd. UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their target price for the company from $167.00 to $180.00 in a report on Friday, December 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, January 24th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Finally, Morgan Stanley lowered their target price on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 24th. Eight equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $176.14.

Read Our Latest Stock Report on JNJ

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $156.76 on Monday. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $175.97. The stock has a 50-day moving average price of $158.20 and a 200 day moving average price of $158.73. The stock has a market capitalization of $377.37 billion, a P/E ratio of 11.35, a P/E/G ratio of 2.63 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The firm had revenue of $21.40 billion during the quarter, compared to analysts’ expectations of $21.02 billion. During the same quarter last year, the business posted $2.35 earnings per share. The firm’s revenue was down 9.7% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be given a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a dividend yield of 3.04%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.